INSTITUTIONAL BIOSAFETY COMMITTEE

UNIVERSITY of WASHINGTON

IBC Meeting Agenda

Date: Wednesday, May 16, 2018

Time: 10:00AM – 12:00PM **Location:** Foege N130A

1. **CALL TO ORDER**
   - Declaration of Quorum

2. **REMINDERS**
   - Public Disclosure & Conflict of Interest Policies

3. **APPROVAL OF MINUTES**
   - April 18, 2018

4. **BIOSAFETY OFFICER REPORT**

5. **INDIVIDUAL PROJECT REVIEWS**

Principal Investigator	Title	Project Type
Clark, Edward	*Lymphocyte Activation (Role of CD22 & Syk Kinase)*	renewal
Crispe, Nick	*Innate Immune Response to Hepatocyte Death; sessile Kupffer cells in liver tolerance; innate immune response in liver*	change
Fink, Susan	*Host-Pathogen Interactions During Viral Infection*	change
Frevert, Charles	*Proteoglycans and Influenza Infection: Gene-targeted mouse models to study versican*	change
Froehner, Stanley	*Froehner Muscular Dystrophy Projects*	renewal
Gu, Liangcai	*Study of small molecule-controlled CAR-T cell activation in mice*	new
Kim, Jeansok	*Using molecular biological approaches to understand fear related behavior in predatory prey interactions*	renewal
Maly, Dustin	*Study of Intracellular Protein Kinases*	change
Murphy, Sean	*NHP Malaria Studies*	new
Mustari, Michael	*Neural Mechanisms for Vision*	renewal
Rettie, Allan	*Functional Characterization of CYP4Z1 and CYP4X1*	new
Starita, Lea	*Brotman Baty Advanced Technology Lab: General Research*	new
Tang, Gale	*Mechanism of Arteriogenesis in Mice and Rats*	renewal
Woodward, Joshua	*Probiotic mediated treatment of metabolic and immune disorders*	renewal

6. **SUBCOMMITTEE REPORTS**

Principal Investigator	Title	Project Type
Becker, Pamela	*Gene Transfer for Patients with Fanconi Anemia Complementation Group A (FANCA)*	renewal
Kiem, Hans-Peter	*A Clinical Trial of Gene-Modified Stem Cells to Generate HIV-Resistant Cells in Conjunction with Standard Chemotherapy for the Treatment of Lymphoma Patients with HIV Infection*	renewal
Shadman, Mazyar	*Autologous transplantation and stem cell based-gene therapy with LVsh5/C46 (CAL-1), a dual anti-HIV lentiviral vector, for the treatment of HIV-associated lymphoma*	new

7. **FOR YOUR INFORMATION**

8. **ISSUES FROM THE FLOOR**

9. **COMMENTS FROM THE PUBLIC**